Dr. Reddy's Laboratories has announced the launch of Colozo (Linaclotide), a first-in-class medication for chronic constipation management in India. The Hyderabad-based pharmaceutical company claims to be the first to introduce this novel therapy in the country, marking a significant expansion of its gastrointestinal portfolio.
Novel Mechanism of Action
Colozo is a guanylate cyclase-C (GC-C) receptor agonist that works by helping the bowel produce more fluid, which softens the stool and makes it easier to pass through the colon. This USFDA-approved medication represents a differentiated approach to treating constipation-related disorders.
The drug is indicated for multiple patient populations, including adults suffering from chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C) in adults, and functional constipation (FC) in pediatric patients aged 6 to 17 years.
Market Positioning and Clinical Evidence
"Colozo is a differentiated, USFDA-approved solution for Chronic Constipation. Backed by robust clinical evidence and promising outcomes, it represents a breakthrough in addressing unmet needs of patients," said M.V. Ramana, CEO, Branded Markets (India and Emerging Markets), Dr. Reddy's Laboratories.
The medication will be available in India under two strengths: 72 mcg and 145 mcg, providing healthcare providers with dosing flexibility for different patient needs.
Strategic Portfolio Expansion
The launch of Colozo follows Dr. Reddy's introduction of BixiBat in India last year, demonstrating the company's continued focus on bringing novel and first-in-class drugs to the Indian market. "The launch of Colozo marks a significant step in our gastrointestinal segment in India and adds to our list of novel and first-in-class drugs," Ramana noted.
This strategic expansion aligns with Dr. Reddy's broader commitment to deliver advanced therapies that meaningfully improve everyday patient care, supporting the company's ambitious goal to serve 1.5 billion patients by 2030.
Market Impact
Dr. Reddy's shares closed 1.65 percent down at Rs 1,263.35 apiece on the BSE on Tuesday, the day of the announcement. The launch represents the company's continued investment in addressing unmet medical needs in the gastrointestinal therapeutic area within the Indian pharmaceutical market.
